Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$469.82M |
$8.18
-0.49%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$466.48M |
$8.48
+2.05%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$464.91M |
$17.21
+1.12%
|
|
KIDS
OrthoPediatrics Corp.
Directly manufactures pediatric orthopedic implants and devices (plates, screws, growing rods, braces), the core product category for the company.
|
$460.10M |
$18.37
-1.82%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$459.99M |
$19.23
+0.29%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$456.46M |
$23.95
+4.47%
|
|
MG
Mistras Group, Inc.
MG provides Laboratory Testing & Advisory Services as part of its inspection and testing offerings.
|
$456.04M |
$14.46
+0.98%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$451.19M |
$6.53
+0.93%
|
|
CYH
Community Health Systems, Inc.
CYH directly provides hospital inpatient and outpatient care services through a network of hospitals and related facilities.
|
$448.38M |
$3.20
-4.19%
|
|
NWBO
Northwest Biotherapeutics, Inc.
NWBO is a cancer-focused biotechnology company developing oncology immunotherapies (DCVax) and related products; tags align with Biotech - Oncology.
|
$444.63M |
$0.30
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$441.40M |
$7.47
+0.34%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$437.98M |
$23.18
+0.32%
|
|
ANGO
AngioDynamics, Inc.
Core product category: vascular intervention devices, including Auryon, AlphaVac, and AngioVac.
|
$430.54M |
$10.46
-5.00%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$430.33M |
$5.01
+3.40%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$427.94M |
$2.94
-3.14%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$425.94M |
$5.49
-3.00%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$418.41M |
$11.00
+1.66%
|
|
CLPT
ClearPoint Neuro, Inc.
ClearPoint's core offerings include neurosurgical navigation hardware and related surgical equipment (e.g., ClearPoint system, Prism Laser Therapy, Velocity Alpha drill).
|
$416.46M |
$14.65
+0.03%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$415.13M |
$33.54
+2.60%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$413.12M |
$8.30
+1.53%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$411.12M |
$6.67
+1.14%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$407.25M |
$3.62
+1.97%
|
|
ETON
Eton Pharmaceuticals, Inc.
KHINDIVI (ET-400), ET-600, ET-700, and ET-800 involve oral/ready formulations (e.g., desmopressin, hydrocortisone, zinc) consistent with the Oral Small Molecule Therapeutics category.
|
$406.02M |
$15.15
-1.69%
|
|
RXST
RxSight, Inc.
RxSight's core offering is the Light Adjustable Lens system and related ophthalmic devices used in premium cataract surgery, which fits Ophthalmology Devices.
|
$401.39M |
$9.81
+0.26%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$399.07M |
$7.39
-1.47%
|
|
AURA
Aura Biosciences, Inc.
Aura's lead oncology program bel-sar is a cancer therapy, targeting solid tumors and advancing in Phase 3.
|
$393.22M |
$6.16
-2.69%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$392.77M |
$3.65
-1.75%
|
|
DMAC
DiaMedica Therapeutics Inc.
Preeclampsia indication places the program within biotech initiatives targeting rare or high-need diseases.
|
$391.54M |
$7.61
-10.95%
|
Showing page 18 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
